Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
TTR-H5223 | Human | Human Transthyretin / Prealbumin Protein, His Tag | ![]() |
![]() ![]() |
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Inotersen sodium | GSK-2998728; ISIS-420915 | Approved | Ionis, Akcea | inotersen sodium | ema | Treatment of stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). |
Akcea Therapeutics Ireland Limited | 2018-07-05 | Transthyretin familial amyloid polyneuropathy (TTR-FAP), Transthyretin amyloidosis | Details |
Patisiran | ALN-18328; ALN-TTR02; GENZ-438027; SAR-438037 | Approved | Alnylam, Sanofi | ONPATTRO | fda | Transthyretin familial amyloid polyneuropathy (TTR-FAP), Transthyretin amyloidosis | ALNYLAM PHARMS INC | 2018-08-10 | Transthyretin familial amyloid polyneuropathy (TTR-FAP), Transthyretin amyloidosis | Details |
Tafamidis Meglumine | Fx-1006A; FX-1006A; PF-06291826; PF-6291826 | Approved | Pfizer | tafamidis | ema | Vyndaqel is indicated for the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment. |
Pfizer Europe MA EEIG | 2011-11-16 | Transthyretin familial amyloid polyneuropathy (TTR-FAP), Transthyretin amyloidosis | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
ION-682884 | AKCEA-TTR-LRx; ION-682884; ION-TTR-LRx; IONIS-TTR-LRx | Phase Ⅲ | Ionis Pharmaceuticals, Akcea | Transthyretin amyloidosis | Details |
PRX-004 | PRX-004 | Phase Ⅰ | Prothena | Transthyretin amyloidosis | Details |
AG-10 | AG-10; BBP-265 | Phase Ⅲ | Stanford University, Bridge, Alexion Pharmaceuticals | Transthyretin amyloidosis | Details |
Vutrisiran | ALN-TTRSC02 | Phase Ⅲ | Alnylam | Transthyretin amyloidosis | Details |
NI-006 | NI-006,NI006 | Phase Ⅰ | Neurimmune | Transthyretin-Related Amyloid Cardiomyopathy | Details |
Revusiran | SAR-438714 | Phase Ⅲ | Alnylam, Sanofi | Transthyretin amyloidosis, Amyloid polyneuropathy | Details |
ALN-TTR01 | ALN-TTR01 | Phase Ⅰ | Alnylam | Transthyretin amyloidosis | Details |
This web search service is supported by Google Inc.